Why use viral vectors instead of traditional vaccines?

They offer stronger T-cell responses, rapid development (critical for pandemics), and flexibility against multiple pathogens by swapping antigens.

What are common viral vectors in vaccine development?

Adenovirus (COVID-19 vaccines), VSV (e.g., Ebola vaccine), and LCMV are widely used.

How do you ensure viral vector safety?

Vectors are replication-deficient (cannot cause disease) and undergo rigorous preclinical toxicity/biodistribution studies.

Can viral vectors overcome pre-existing immunity?

Yes, by using rare human serotypes (e.g., Ad26, ChAdOx1) or non-human vectors (e.g., VSV, LCMV).

How do you optimize viral vector immunogenicity?

By enhancing antigen expression (strong promoters), adding adjuvants, or targeting dendritic cells (e.g., LCMV vectors).

Can viral vectors be used for non-infectious diseases?

Yes, for cancer immunotherapy (e.g., expressing tumor antigens) and chronic infections (e.g., HIV, HBV).

Why partner with Creative Biolabs for viral vector vaccines?

We offer end-to-end solutions—from vector design to GMP manufacturing—with validated platforms (adenovirus, VSV, hybrid systems).

Viral Vector Vaccine Solutions

At Creative Biolabs, we provide comprehensive viral vector vaccine design services, which are critical for preclinical development. We specialize in leveraging diverse viral vector platforms, including hPIV2, VACV, Ad, AAV, and others, to engineer novel vaccines. Our expertise extends to developing "prime-boost" strategies, where we integrate viral vectors with recombinant antigens or DNA vaccines to enhance immune responses. Our approach involves careful selection of low pathogenic viruses for vector development and a thorough assessment of potential effects by understanding epidemiological and virological characteristics, ensuring robust preclinical evaluation for your vaccine candidates.

Talk To Our Vaccine Experts View Services Available products

End-to-end viral vector vaccine solutions

What is A Viral Vector Vaccine?

A viral vector vaccine utilizes engineered, non-pathogenic viruses as delivery vehicles ("vectors") to transport genetic material encoding target antigens into host cells. These modified vectors—commonly derived from adenoviruses, vesicular stomatitis virus (VSV), or poxviruses—lack replication capability but efficiently infect cells and express the inserted antigen gene. This triggers robust immune responses by mimicking natural infection: intracellular antigen production enables MHC-I presentation for cytotoxic T-cell activation, while secreted antigens stimulate antibody production and helper T-cells. Key advantages include strong cellular immunity induction, precise antigen delivery without adjuvants, and rapid adaptability to emerging pathogens through genetic cassette swapping. Viral vectors are particularly valuable for complex targets like intracellular pathogens and cancers, where traditional vaccines often fail. Creative Biolabs leverages this technology to develop vaccines against infectious diseases (e.g., COVID-19, Ebola) and cancer immunotherapy candidates.

Comprehensive Viral Vector Vaccine Preclinical Solutions

Creative Biolabs offers comprehensive viral vector vaccine services. We assist in vector selection, like adenovirus or lentivirus, based on their unique features. Our experts optimize gene insertion and expression within the vector. We conduct in - depth preclinical studies on immunogenicity and safety. With years of experience, we ensure high - quality, customized solutions for clients' vaccine development needs.

Comprehensive Service Portfolio

Vaccine Design Adjuvant selection Analysis & ValidationFormulation Development Preclinical Testing

Customized Viral Vector Vaccine Design

Pathogen-Tailored Vector Engineering
Optimized adenovirus/VSV vectors engineered for specific pathogens (e.g., HIV gp120, SARS-CoV-2 Spike) or cancer antigens (neoantigens), with codon optimization and enhanced promoters for robust antigen expression.
Multi-Antigen & Hybrid Vector Systems
Development of multivalent vectors co-expressing 2-4 antigens (e.g., influenza HA/NA/M2e) or hybrid platforms (e.g., adenovirus-poxvirus) to combat viral escape mutants and broaden immune coverage.
Safety-Focused Vector Modifications
Replication-deficient designs with E1/E3 deletions, neuroattenuation (VSV-G pseudotyping), and promoter tuning to minimize reactogenicity while maximizing immunogenicity.

Adjuvant Development & Optimization

Vector-Specific Adjuvant Screening
Evaluation of TLR agonists (e.g., TLR3/7/9), STING activators, and cytokine adjuvants (IL-12, GM-CSF) to enhance viral vector immunogenicity without compromising safety.
Delivery-Integrated Formulations
Co-encapsulation of adjuvants with viral vectors (e.g., adenovirus/AAV) in LNPs or polymeric nanoparticles to synchronize delivery and amplify immune responses.
Immune Profiling & Synergy Optimization
Mechanistic studies measuring adjuvant effects on T-cell polarization (Th1/Th2), neutralizing antibodies, and memory B/T-cell formation in preclinical models.

Analytical Development & Preclinical Validation

Comprehensive Vector Characterization
Quantification of viral titer (TCID50, qPCR), purity analysis (HPLC-SEC, SDS-PAGE), and structural integrity assessment (DLS, TEM) to ensure batch consistency and potency.
Immunogenicity Profiling
In vitro (PBMC activation, cytokine multiplex) and in vivo (rodent/NHP) evaluation of neutralizing antibodies, T-cell responses (ELISpot, ICS), and challenge protection against target pathogens.
Process-Related Impurity Control
Sensitive detection of host cell DNA/RNA, residual proteins, and endotoxins to meet GMP standards for clinical translation.

Formulation & Process Development

Advanced Vector Formulation
Development of stable liquid and lyophilized formulations using proprietary excipients to maintain viral vector potency during storage and transport.
Scalable Production Platform
GMP-compliant manufacturing processes utilizing adherent/suspension cell culture systems for high-yield vector production (up to 200L scale).
Downstream Optimization
Innovative purification technologies including chromatography and TFF to achieve high vector purity (>95%) while maintaining infectivity.

Preclinical Testing

Challenge Study Validation
Pathogen-specific protection models with quantitative efficacy endpoints (viral load reduction, survival rate improvement).
Biodistribution & Safety Profiling
Studies evaluating vector persistence, organ tropism, and local/systemic reactogenicity.

Featured Viral Vector Vaccine Design Services

hPIV2 Vector Technology

Low immunogenicity, efficient mucosal delivery;
Ideal for respiratory pathogen vaccines, with stable transgene expression.

VACV or VV based Vaccine-Vector Design

Large insert capacity, strong immunogenicity;
Supports multi-antigen delivery, proven in vaccine development against diverse viruses.

Ad based Vaccine-Vector Design

High transduction efficiency, broad tropism;
Replication-defective variants for safety, optimized for rapid immune response induction.

AAV based Vaccine-Vector Design

Long-term transgene expression, minimal toxicity;
Various serotypes for tissue-specific targeting, suitable for chronic disease vaccines.

CMV based Vaccine-Vector Design

Persistent antigen presentation, robust cellular immunity;
Effective for intracellular pathogens, with natural tropism for immune cells.

SeV based Vaccine-Vector Design

Efficient cytoplasmic delivery, mucosal immunity induction;
Non-integrating, low pathogenicity, ideal for respiratory vaccines.

Retrovirus based Vaccine-Vector Design

Stable genomic integration, long-term expression;
Suitable for cancer vaccines, with modified envelopes for cell-specific targeting.

Poxvirus based Vaccine-Vector Design

Large cloning capacity, heat stability;
Supports multi-epitope vaccines, with established safety in human trials.

Alphavirus based Vaccine-Vector Design

High transient expression, strong immunogenicity;
Self-replicating RNA, rapid production, effective for emerging threats.

Lentivirus based Vaccine-Vector Design

Non-dividing cell transduction, stable expression;
Low immunogenicity, suitable for chronic infection and cancer vaccine development.

NDV based Vaccine-Vector Design

Natural oncolytic activity, systemic immunity;
Safe in humans, effective for cancer and poultry disease vaccines.

HSV based Vaccine-Vector Design

Neural cell tropism, latency potential;
Engineered for reduced pathogenicity, useful for neurotropic virus vaccines.

MV based Vaccine-Vector Design

Strong immune stimulation, broad cell tropism;
Attenuated strains ensure safety, effective for measles-related and vector vaccines.

SFV based Vaccine-Vector Design

Rapid and high-level protein expression;
Self-limiting replication, low persistence, suitable for acute pathogen vaccine development.

How Dose Viral Vector Vaccine Solution Work?

1. Antigen Design and Optimization

Pathogen genome analysis based on high-throughput sequencing platform
AI online platform predicts highly immunogenic epitopes
Optimizing and modifying candidate antigens to enhance their immunogenicity and stability.

2. Immunization Strategy Development

Outer Membrane Vesicle Platform induces antigen expression
Optimization of adjuvant compatibility (aluminum adjuvant, TLR agonist)
Delivery system customization (nanoparticles/liposomes)

3. Immunogenicity Assessment

Humoral immunity testing (IgG/IgA subtypes, neutralizing antibody titers)
Cellular immune assay (Th1/Th2/Th17 response profile)
ADCP/ADCD functional verification

4. Animal Model Verification

Customized challenge model (mouse/guinea pig/rabbit)
Protection effectiveness evaluation (LD50, Totally Synthetic load monitoring)
Safety assessment (local/systemic toxicity)

5. Report

Screening analysis reports
Test data reports
Project design document

Online Inquiry

Getting Started with Your Vaccine Project

Professional Vaccine Solution platform

Antigen Prediction System Platform

Our Antigen Prediction System Platform integrates advanced bioinformatics and computational biology tools to identify and prioritize immunogenic antigens. Leveraging cutting-edge algorithms, we analyze pathogen genomes or cancer markers to predict key epitopes that elicit robust immune responses. This platform enables the rational design of vaccines by pinpointing high-potency antigens, significantly accelerating the development process for bacterial, viral, fungal, parasitic, and cancer-targeted vaccines. By combining traditional immunology with state-of-the-art predictive modeling, we ensure optimal antigen selection for maximum immunogenicity and efficacy.

Protein Expression Platform

The Protein Expression Platform at Creative Biolabs offers versatile solutions for producing recombinant antigens using multiple expression systems. We specialize in optimizing bacterial (e.g., E. coli), yeast, insect, and mammalian cell systems to meet diverse production needs. Our expertise in genetic engineering allows us to tailor expression vectors, culture conditions, and purification protocols for high-yield, biologically active proteins. Whether for preclinical research or large-scale manufacturing, our platform ensures consistent production of immunogenic proteins, supporting the development of vaccines with enhanced stability and immunogenicity. We seamlessly integrate expression technologies with downstream analytical and formulation services to streamline the vaccine development pipeline.

Modular Delivery System Platform

Our Modular Delivery System Platform is designed to enhance vaccine potency and delivery efficiency through customizable, multi-component formulations. Focused on optimizing delivery mechanisms, we develop lipid-based nanoparticles, viral-like particles (VLPs), and other nano-carriers to protect antigens, improve cellular uptake, and modulate immune responses. The modular design allows for precise integration of adjuvants, targeting ligands, and protective matrices, enabling tailor-made systems for various vaccine types—from prophylactic to therapeutic.

Why Choose Our Viral Vector Vaccine Services?

Comprehensive Vector Platform

We offer adenovirus, VSV, and poxvirus vectors with optimized immunogenicity and safety profiles for diverse vaccine applications.

Customized Vector Engineering

Proprietary capsid/surface modifications enable tissue-specific targeting and enhanced antigen presentation.

Rapid Response Development

Ready-to-use vector backbones allow vaccine prototyping within 4-6 weeks for emerging pathogens.

Available Products

Antigen Products Antibody Products Adjuvant Products Delivery System related Products

Array Kits Cell Culture Medium Proudcts

FAQs About Our Viral Vector Vaccine Solution

Why use viral vectors instead of traditional vaccines?

They offer stronger T-cell responses, rapid development (critical for pandemics), and flexibility against multiple pathogens by swapping antigens.
What are common viral vectors in vaccine development?

Adenovirus (COVID-19 vaccines), VSV (e.g., Ebola vaccine), and LCMV are widely used.
How do you ensure viral vector safety?

Vectors are replication-deficient (cannot cause disease) and undergo rigorous preclinical toxicity/biodistribution studies.
Can viral vectors overcome pre-existing immunity?

Yes, by using rare human serotypes (e.g., Ad26, ChAdOx1) or non-human vectors (e.g., VSV, LCMV).
How do you optimize viral vector immunogenicity?

By enhancing antigen expression (strong promoters), adding adjuvants, or targeting dendritic cells (e.g., LCMV vectors).
Can viral vectors be used for non-infectious diseases?

Yes, for cancer immunotherapy (e.g., expressing tumor antigens) and chronic infections (e.g., HIV, HBV).
Why partner with Creative Biolabs for viral vector vaccines?

We offer end-to-end solutions—from vector design to GMP manufacturing—with validated platforms (adenovirus, VSV, hybrid systems).

Related Resources

Download Resources

Literature Center

Podcast